17 Citations (Scopus)

Abstract

Type 2 diabetes has become a major health issue worldwide. Chronic hyperglycemia induces a low-grade inflammation that, on top of other mechanisms, leads to endothelial dysfunction. Mounting evidence suggests that DNA methylation, post-translational modifications of histones, and long non-coding RNAs play an important role in the initiation, maintenance, and progression of both macro- and micro-vascular complications of diabetes. Long-term exposure to hyperglycemia induces epigenetic changes that could become irreversible, a phenomenon known as the ‘metabolic memory.’ Whether epigenetic-based therapies could be used to slow or limit the progression of cardiovascular disease remains unclear. While non-coding RNAs are currently investigated as potential biomarkers that predict diabetic cardiovascular disease incidence and progression, their therapeutic role is only hypothetical. In this review, we highlight the latest findings in experimental and clinical studies relevant to epigenetics and cardiovascular disease in diabetes.

Original languageEnglish
Article number108
JournalCurrent Diabetes Reports
Volume15
Issue number12
DOIs
Publication statusPublished - 1 Dec 2015

Fingerprint

Epigenomics
Cardiovascular Diseases
Hyperglycemia
Blood Vessels
Long Noncoding RNA
Untranslated RNA
DNA Methylation
Diabetes Complications
Post Translational Protein Processing
Histones
Type 2 Diabetes Mellitus
Disease Progression
Biomarkers
Maintenance
Inflammation
Incidence
Therapeutics

Keywords

  • Cardiovascular complications of diabetes
  • Cardiovascular disease
  • Diabetes
  • Diabetic cardiomyopathy
  • Epigenetics
  • Macrovascular complications of diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{02b696a0ec3c4d9b80430203489d35a5,
title = "Epigenetics and Cardiovascular Disease in Diabetes",
abstract = "Type 2 diabetes has become a major health issue worldwide. Chronic hyperglycemia induces a low-grade inflammation that, on top of other mechanisms, leads to endothelial dysfunction. Mounting evidence suggests that DNA methylation, post-translational modifications of histones, and long non-coding RNAs play an important role in the initiation, maintenance, and progression of both macro- and micro-vascular complications of diabetes. Long-term exposure to hyperglycemia induces epigenetic changes that could become irreversible, a phenomenon known as the ‘metabolic memory.’ Whether epigenetic-based therapies could be used to slow or limit the progression of cardiovascular disease remains unclear. While non-coding RNAs are currently investigated as potential biomarkers that predict diabetic cardiovascular disease incidence and progression, their therapeutic role is only hypothetical. In this review, we highlight the latest findings in experimental and clinical studies relevant to epigenetics and cardiovascular disease in diabetes.",
keywords = "Cardiovascular complications of diabetes, Cardiovascular disease, Diabetes, Diabetic cardiomyopathy, Epigenetics, Macrovascular complications of diabetes",
author = "Jennifer Pasquier and Jessica Hoarau and Fakhro, {Khalid Adnan Mohamed A.} and Tabrizi, {Arash Rafii} and {Abi Khalil}, Charbel",
year = "2015",
month = "12",
day = "1",
doi = "10.1007/s11892-015-0677-3",
language = "English",
volume = "15",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - Epigenetics and Cardiovascular Disease in Diabetes

AU - Pasquier, Jennifer

AU - Hoarau, Jessica

AU - Fakhro, Khalid Adnan Mohamed A.

AU - Tabrizi, Arash Rafii

AU - Abi Khalil, Charbel

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Type 2 diabetes has become a major health issue worldwide. Chronic hyperglycemia induces a low-grade inflammation that, on top of other mechanisms, leads to endothelial dysfunction. Mounting evidence suggests that DNA methylation, post-translational modifications of histones, and long non-coding RNAs play an important role in the initiation, maintenance, and progression of both macro- and micro-vascular complications of diabetes. Long-term exposure to hyperglycemia induces epigenetic changes that could become irreversible, a phenomenon known as the ‘metabolic memory.’ Whether epigenetic-based therapies could be used to slow or limit the progression of cardiovascular disease remains unclear. While non-coding RNAs are currently investigated as potential biomarkers that predict diabetic cardiovascular disease incidence and progression, their therapeutic role is only hypothetical. In this review, we highlight the latest findings in experimental and clinical studies relevant to epigenetics and cardiovascular disease in diabetes.

AB - Type 2 diabetes has become a major health issue worldwide. Chronic hyperglycemia induces a low-grade inflammation that, on top of other mechanisms, leads to endothelial dysfunction. Mounting evidence suggests that DNA methylation, post-translational modifications of histones, and long non-coding RNAs play an important role in the initiation, maintenance, and progression of both macro- and micro-vascular complications of diabetes. Long-term exposure to hyperglycemia induces epigenetic changes that could become irreversible, a phenomenon known as the ‘metabolic memory.’ Whether epigenetic-based therapies could be used to slow or limit the progression of cardiovascular disease remains unclear. While non-coding RNAs are currently investigated as potential biomarkers that predict diabetic cardiovascular disease incidence and progression, their therapeutic role is only hypothetical. In this review, we highlight the latest findings in experimental and clinical studies relevant to epigenetics and cardiovascular disease in diabetes.

KW - Cardiovascular complications of diabetes

KW - Cardiovascular disease

KW - Diabetes

KW - Diabetic cardiomyopathy

KW - Epigenetics

KW - Macrovascular complications of diabetes

UR - http://www.scopus.com/inward/record.url?scp=84944071900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944071900&partnerID=8YFLogxK

U2 - 10.1007/s11892-015-0677-3

DO - 10.1007/s11892-015-0677-3

M3 - Review article

VL - 15

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 12

M1 - 108

ER -